Macrófitos da Ilha das Flores

XIII Expedição Científica do Departamento de Biologia - Flores e Corvo 2007.As ribeiras e lagoas das ilhas das Flores e Corvo foram prospectadas para a realização de um levantamento de macrófitos durante a Expedição às Ilhas das Flores e Corvo/2007 do Departamento de Biologia. Foram identificadas 43 espécies, 35 nas Flores e 13 no Corvo, das quais 15 são novos registos para o Arquipélago e 3 foram encontradas pela primeira vez no grupo ocidental. No entanto, a riqueza específica encontrada é baixa, comparativamente a sistemas equivalentes na Europa Continental

Speckle Space-Time Covariance in High-Contrast Imaging

We introduce a new framework for point-spread function (PSF) subtraction based on the spatio-temporal variation of speckle noise in high-contrast imaging data where the sampling timescale is faster than the speckle evolution timescale. One way that space-time covariance arises in the pupil is as atmospheric layers translate across the telescope aperture and create small, time-varying perturbations in the phase of the incoming wavefront. The propagation of this field to the focal plane preserves some of that space-time covariance. To utilize this covariance, our new approach uses a Karhunen-Lo\'eve transform on an image sequence, as opposed to a set of single reference images as in previous applications of Karhunen-Lo\'eve Image Processing (KLIP) for high-contrast imaging. With the recent development of photon-counting detectors, such as microwave kinetic inductance detectors (MKIDs), this technique now has the potential to improve contrast when used as a post-processing step. Preliminary testing on simulated data shows this technique can improve contrast by at least 10-20% from the original image, with significant potential for further improvement. For certain choices of parameters, this algorithm may provide larger contrast gains than spatial-only KLIP.Comment: Accepted to A

Does Research from Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer Treatment Translate into Access to Treatments for Patients in the "Real World"? A Systematic Review

CONTEXT: Since 2015 there have been major advances in the management of primary metastatic hormone-sensitive prostate cancer (mHSPC) following the publication of key clinical trials that demonstrated significant clinical benefits with docetaxel chemotherapy or novel hormone therapy (NHT) in addition to androgen deprivation therapy (ADT). Despite these advances, there is evidence to show that these treatments are not being utilised for mHSPC in clinical practice. OBJECTIVE: To determine the utilisation of docetaxel and NHT in mHSPC in routine practice and the determinants of variation in their use. EVIDENCE ACQUISITION: MEDLINE and Embase were searched systematically for studies on utilisation of treatments for primary mHSPC that were based on regional or national data sets and published after January 2005. Study results were summarised using a narrative synthesis. EVIDENCE SYNTHESIS: Thirteen papers were included in the analysis, six full-text articles and seven abstracts, on studies that included a total of 166 876 patients. The utilisation rate of treatment intensification with either docetaxel or NHT (enzalutamide, apalutamide, or abiraterone) in addition to ADT ranged from 9.3% to 38.1% across the studies. Younger, White patients with fewer comorbidities and living in more urban settings were more likely to be prescribed treatment intensification. Patients treated in private academic institutions by oncologists were more likely to receive docetaxel or NHT. Socioeconomic status did not impact receipt of systemic therapy. NHT utilisation rates appear to have increased over time. CONCLUSIONS: These results highlight the need to change the approach to the treatment of primary mHSPC in the real world by harnessing the practice-changing results from recent trials in this setting to optimise upfront systemic therapy for this patient population. PATIENT SUMMARY: We reviewed the use of treatments for primary metastatic hormone-sensitive prostate cancer that showed a benefit in key clinical trials. We found that these treatments are underused, particularly among certain patient groups

Real-world outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: A retrospective cohort study.

PURPOSE: Real-World Data (RWD) studies are increasingly used to support regulatory approvals, reimbursement decisions, and changes in clinical practice for novel cancer drugs. However, few studies have systematically appraised their quality or compared outcomes to pivotal trials. METHODS: All RWD studies (2010-2019) for drugs approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) from 2010 to 2015 for solid organ tumours in the non-curative setting were identified. Quality assessment was undertaken using the Newcastle Ottawa Scale. Survival differences between each RWD study and the pivotal trial were determined using a related sample Wilcoxon signed-rank test. RESULTS: 293 RWD studies for 45 of the 57 drug indications approved by the FDA/EMA were identified. The most common tumour types were prostate cancer (29%, n = 86) and melanoma (15%, n = 43). A quarter of the studies had industry funding. No high-quality studies were identified, and 78% were low quality. Comparative survival analysis between RWD and pivotal trials was possible for 224 studies (37 drug indications). Differences in median survival between the RWD studies and their corresponding trial ranged from -32 months to 21 months (IQR -4·2 months to 1·6 months). Low-quality studies were more likely to report superior survival outcomes (23%) compared to higher quality studies (8%) (p = 0.02). CONCLUSION: RWD study quality for novel cancer drugs is low and of insufficient rigour to inform reimbursement decisions and clinical practice. RWD studies seeking publication should provide a completed quality assessment tool on submission. Greater investment in properly designed RWD studies is required

The MKID Exoplanet Camera for Subaru SCExAO

We present the MKID Exoplanet Camera (MEC), a z through J band (800 - 1400 nm) integral field spectrograph located behind The Subaru Coronagraphic Extreme Adaptive Optics (SCExAO) at the Subaru Telescope on Maunakea that utilizes Microwave Kinetic Inductance Detectors (MKIDs) as the enabling technology for high contrast imaging. MEC is the first permanently deployed near-infrared MKID instrument and is designed to operate both as an IFU, and as a focal plane wavefront sensor in a multi-kHz feedback loop with SCExAO. The read noise free, fast time domain information attainable by MKIDs allows for the direct probing of fast speckle fluctuations that currently limit the performance of most high contrast imaging systems on the ground and will help MEC achieve its ultimate goal of reaching contrasts of $10^{-7}$ at 2$\lambda / D$. Here we outline the instrument details of MEC including the hardware, firmware, and data reduction and analysis pipeline. We then discuss MEC's current on-sky performance and end with future upgrades and plans.Comment: To be published in Publications of the Astronomical Society of the Pacifi

Optical and Near-IR Microwave Kinetic Inductance Detectors (MKIDs) in the 2020s

Optical and near-IR Microwave Kinetic Inductance Detectors, or MKIDs, are superconducting photon counting detectors capable of measuring the energy and arrival time of individual OIR photons without read noise or dark current. In this whitepaper we will discuss the current status of OIR MKIDs and MKID-based instruments.Comment: Astro2020 APC Whitepaper. 16 pages, 10 figure

MKID Exoplanet Camera for Subaru SCExAO

We present the MKID Exoplanet Camera (MEC), a z through J band (800–1400 nm) integral field spectrograph located behind The Subaru Coronagraphic Extreme Adaptive Optics (SCExAO) at the Subaru Telescope on Maunakea that utilizes Microwave Kinetic Inductance Detectors (MKIDs) as the enabling technology for high contrast imaging. MEC is the first permanently deployed near-infrared MKID instrument and is designed to operate both as an IFU, and as a focal plane wavefront sensor in a multi-kHz feedback loop with SCExAO. The read noise free, fast time domain information attainable by MKIDs allows for the direct probing of fast speckle fluctuations that currently limit the performance of most high contrast imaging systems on the ground and will help MEC achieve its ultimate goal of reaching contrasts of 10⁻⁷ at 2 λ/D. Here we outline the instrument details of MEC including the hardware, firmware, and data reduction and analysis pipeline. We then discuss MEC's current on-sky performance and end with future upgrades and plans